Rovelizumab Biosimilar – Anti-ITGAL, CD11a, ITGB2, CD18 mAb – Research Grade

Description of Rovelizumab Biosimilar - Anti-ITGAL, CD11a, ITGB2, CD18 mAb - Research Grade

Introduction

Rovelizumab Biosimilar, also known as Anti-ITGAL, CD11a, ITGB2, CD18 mAb, is a monoclonal antibody that targets the integrin family of proteins. This biosimilar is a research grade version of the original Rovelizumab drug, which has been used in clinical trials for the treatment of various inflammatory and autoimmune diseases. In this article, we will discuss the structure, activity, and potential applications of Rovelizumab Biosimilar.

Structure of Rovelizumab Biosimilar

Rovelizumab Biosimilar is a recombinant humanized monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It is composed of two heavy chains and two light chains, which are linked together by disulfide bonds. The heavy chains consist of a constant region (Fc) and a variable region (Fab), while the light chains only have a variable region. The variable regions of Rovelizumab Biosimilar are responsible for its specificity and binding to its target molecules.

Activity of Rovelizumab Biosimilar

Rovelizumab Biosimilar specifically targets the integrin family of proteins, which are cell adhesion molecules involved in various cellular processes, such as cell migration, proliferation, and differentiation. It specifically binds to the αLβ2 integrin, also known as lymphocyte function-associated antigen-1 (LFA-1), which is expressed on the surface of leukocytes. This binding prevents the interaction of LFA-1 with its ligands, such as intercellular adhesion molecule-1 (ICAM-1), thus inhibiting leukocyte activation and migration.

Rovelizumab Biosimilar has been shown to have potent anti-inflammatory activity in various preclinical and clinical studies. It has been found to reduce the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, and to inhibit leukocyte infiltration into inflamed tissues. This makes it a potential therapeutic option for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

Potential Applications of Rovelizumab Biosimilar

Rovelizumab Biosimilar has been primarily studied for its potential use in the treatment of rheumatoid arthritis (RA). In a phase II clinical trial, Rovelizumab Biosimilar was found to be safe and effective in reducing the signs and symptoms of RA, as well as improving physical function in patients who had an inadequate response to methotrexate. It also showed a favorable safety profile, with no serious adverse events reported.

Apart from RA, Rovelizumab Biosimilar has also shown promising results in other inflammatory and autoimmune diseases. In a phase II clinical trial, it was found to be effective in reducing disease activity and improving clinical outcomes in patients with psoriasis. It has also been studied for its potential use in inflammatory bowel disease, with preclinical data showing a significant reduction in disease severity and inflammation.

Conclusion

Rovelizumab Biosimilar is a recombinant humanized monoclonal antibody that targets the integrin family of proteins. It has potent anti-inflammatory activity and has shown promising results in various preclinical and clinical studies. Its primary target is the αLβ2 integrin, which is expressed on the surface of leukocytes and is involved in various inflammatory processes. Rovelizumab Biosimilar has been primarily studied for its potential use in the treatment of rheumatoid arthritis, but it also holds promise for the treatment of other inflammatory and autoimmune diseases. Further clinical studies are needed to fully evaluate its safety and efficacy in these diseases.